Gynecologic oncology最新文献_第4页

Evaluating patient perspectives about the acceptability of a novel prognostic gene expression signature for high grade serous ovarian cancer: The OTTA-SPOT study 评估患者对高级别浆液性卵巢癌新预后基因表达特征可接受性的看法：OTTA-SPOT研究

IF 4.1 2区医学 Q1 OBSTETRICS & GYNECOLOGY

Gynecologic oncology

Pub Date : 2025-12-05 DOI: 10.1016/j.ygyno.2025.11.023

Holly E. Evans , Amber-Marie Firriolo , Rachel Houweling , Lauren Kelada , Gill Stannard , Jacinta Frawley , Brittany C. McGill , Susan J. Ramus , Yeh Chen Lee , Michael Friedlander , Jennifer Duggan , Claire E. Wakefield

Objective

The Ovarian Tumor Tissue Analysis consortium - Stratified Prognosis of Ovarian Tumors (OTTA-SPOT) 101 gene expression signature, predicts 5-year survival on a tumor biopsy at diagnosis and identifies the 20 % of patients with a 10 % probability of 5-year survival with standard of care therapy, who may benefit from alternate treatments. This study aims to understand how patients with ovarian cancer perceive the potential advantages and disadvantages of OTTA-SPOT, their willingness for the test, and preferred methods of receiving test results.

Methods

Participants were eligible if they had a diagnosis of ovarian cancer and resided in Australia or New Zealand. Participants completed a mixed-methods questionnaire, co-designed with consumers, which investigated their perspectives about prognostic tests for ovarian cancer. Participants could opt-in to a 1–1.5-h online focus group to discuss their perspectives further.

Results

Thirty-three participants completed the online questionnaire. Participants perceived the potential advantages of the prognostic test outweighed the disadvantages, and 88 % would be ‘very willing’ or ‘willing’ to undergo prognostic testing if available. Nine participants took part in focus groups. We developed four themes from thematic analysis of these discussions: (1) Cancer journey and context, (2) Advantages and disadvantages of knowing prognosis, (3) The complexities of when to receive prognostic information, and (4) Communication and service delivery.

Conclusion

Participants with ovarian cancer viewed prognostic testing positively. However, successful implementation will require a patient-centred approach that accommodates diverse preferences around how the test is introduced, and results are communicated.

目的卵巢肿瘤组织分析联盟-卵巢肿瘤分层预后（OTTA-SPOT） 101基因表达特征，在诊断时预测肿瘤活检的5年生存率，并确定20%的患者在标准护理治疗下的5年生存率为10%，他们可能从替代治疗中受益。本研究旨在了解卵巢癌患者如何看待OTTA-SPOT的潜在优缺点，他们是否愿意接受这项检测，以及接受检测结果的首选方法。方法研究对象为居住在澳大利亚或新西兰的卵巢癌患者。参与者完成了一份与消费者共同设计的混合方法问卷，调查了他们对卵巢癌预后测试的看法。参与者可以选择参加一个1 - 1.5小时的在线焦点小组，进一步讨论他们的观点。结果33名参与者完成了在线问卷调查。参与者认为预后测试的潜在优点大于缺点，88%的人“非常愿意”或“愿意”接受预后测试，如果可以的话。九名参与者参加了焦点小组。通过对这些讨论的专题分析，我们提出了四个主题：(1)癌症历程和背景；(2)了解预后的利弊；(3)何时接收预后信息的复杂性；(4)沟通和服务提供。结论卵巢癌患者对预后检测的评价是积极的。然而，成功的实施将需要一种以患者为中心的方法，以适应在如何引入测试和结果沟通方面的不同偏好。

{"title":"Evaluating patient perspectives about the acceptability of a novel prognostic gene expression signature for high grade serous ovarian cancer: The OTTA-SPOT study","authors":"Holly E. Evans , Amber-Marie Firriolo , Rachel Houweling , Lauren Kelada , Gill Stannard , Jacinta Frawley , Brittany C. McGill , Susan J. Ramus , Yeh Chen Lee , Michael Friedlander , Jennifer Duggan , Claire E. Wakefield","doi":"10.1016/j.ygyno.2025.11.023","DOIUrl":"10.1016/j.ygyno.2025.11.023","url":null,"abstract":"<div><h3>Objective</h3><div>The Ovarian Tumor Tissue Analysis consortium - Stratified Prognosis of Ovarian Tumors (OTTA-SPOT) 101 gene expression signature, predicts 5-year survival on a tumor biopsy at diagnosis and identifies the 20 % of patients with a 10 % probability of 5-year survival with standard of care therapy, who may benefit from alternate treatments. This study aims to understand how patients with ovarian cancer perceive the potential advantages and disadvantages of OTTA-SPOT, their willingness for the test, and preferred methods of receiving test results.</div></div><div><h3>Methods</h3><div>Participants were eligible if they had a diagnosis of ovarian cancer and resided in Australia or New Zealand. Participants completed a mixed-methods questionnaire, co-designed with consumers, which investigated their perspectives about prognostic tests for ovarian cancer. Participants could opt-in to a 1–1.5-h online focus group to discuss their perspectives further.</div></div><div><h3>Results</h3><div>Thirty-three participants completed the online questionnaire. Participants perceived the potential advantages of the prognostic test outweighed the disadvantages, and 88 % would be ‘very willing’ or ‘willing’ to undergo prognostic testing if available. Nine participants took part in focus groups. We developed four themes from thematic analysis of these discussions: (1) Cancer journey and context, (2) Advantages and disadvantages of knowing prognosis, (3) The complexities of when to receive prognostic information, and (4) Communication and service delivery.</div></div><div><h3>Conclusion</h3><div>Participants with ovarian cancer viewed prognostic testing positively. However, successful implementation will require a patient-centred approach that accommodates diverse preferences around how the test is introduced, and results are communicated.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"204 ","pages":"Pages 150-157"},"PeriodicalIF":4.1,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145690381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Co-targeting the PI3K-Akt pathway improves response to MEK inhibition in low-grade serous ovarian cancer cell lines 共同靶向PI3K-Akt通路可改善低级别浆液性卵巢癌细胞系对MEK抑制的应答

IF 4.1 2区医学 Q1 OBSTETRICS & GYNECOLOGY

Gynecologic oncology

Pub Date : 2025-12-05 DOI: 10.1016/j.ygyno.2025.11.016

Rebekah M. Peplinski, Jesse D. Riordan, Jacob L. Schillo, Elizabeth C. Hannan, Silvana Pedra Nobre, Yasmin A. Lyons, Keely K. Ulmer, Michael J. Goodheart, Adam J. Dupuy

Objective

Low-grade serous ovarian cancer (LGSOC) frequently harbors genetic alterations that activate the MAPK pathway, providing an oncogenic target for therapeutic intervention. Recent clinical trials utilizing inhibitors of MEK (a key mediator of MAPK signaling), particularly trametinib or avutometinib/defactinib combination, have shown efficacy in patients with recurrent LGSOC. Unfortunately, however, nearly all patients eventually develop therapeutic resistance and progressive disease, which confers a dismal prognosis. Here, we aim to characterize biological responses of LGSOC to MEK inhibition at the molecular level.

Methods

We performed a kinome-focused CRISPR knockout screen in LGSOC cell lines to identify synthetic lethal interactions between trametinib treatment and loss of specific protein kinases. Candidates were evaluated using western blotting and cell viability assays.

Results

CRISPR kinome screens identified several protein kinases, particularly within the PI3K-Akt pathway, whose loss correlated with outgrowth of trametinib-resistant LGSOC cell populations, indicative of synthetic lethal interaction. Western blotting confirmed upregulation of Akt signaling upon MEK inhibition in a panel of LGSOC cell lines, and preventing this upregulation by co-inhibiting AKT with capivasertib produced synergistic antiproliferative effects in vitro.

Conclusion

LGSOC responds to MEK inhibition by upregulating PI3K-Akt signaling, thereby promoting cell survival and proliferation. Our research identified significant upregulation of the PI3K-Akt pathway in response to MEK inhibition. While targeted inhibition of AKT had minimal impact alone, combination with MEK inhibitors produced strong synergistic suppression of proliferation in LGSOC cells. This combination strategy could potentially be used to prevent or reverse the emergence of MEK inhibitor resistance in LGSOC patients.

目的：低级别浆液性卵巢癌（LGSOC）经常存在激活MAPK通路的基因改变，为治疗干预提供了一个致癌靶点。最近的临床试验使用MEK抑制剂（MAPK信号的关键介质），特别是曲美替尼或阿伏替尼/德法替尼联合，已经显示出对复发性LGSOC患者的疗效。然而，不幸的是，几乎所有的患者最终都会产生治疗耐药性和疾病进展，这使得预后很差。在这里，我们的目的是在分子水平上表征LGSOC对MEK抑制的生物学反应。方法我们在LGSOC细胞系中进行了以激酶为中心的CRISPR敲除筛选，以鉴定曲美替尼治疗与特异性蛋白激酶缺失之间的合成致死相互作用。使用western blotting和细胞活力测定对候选物进行评估。结果scrispr kinome筛选发现了几种蛋白激酶，特别是在PI3K-Akt通路中，其缺失与曲美替尼耐药LGSOC细胞群的生长相关，表明合成致死相互作用。Western blotting证实，在一组LGSOC细胞系中，MEK抑制可使Akt信号上调，并且通过与capivasertib共同抑制Akt可在体外产生协同抗增殖作用。结论lgsoc通过上调PI3K-Akt信号通路响应MEK抑制，从而促进细胞存活和增殖。我们的研究发现，在MEK抑制的情况下，PI3K-Akt通路显著上调。虽然靶向抑制AKT单独作用很小，但与MEK抑制剂联合使用可产生很强的协同抑制LGSOC细胞的增殖。这种联合策略可能用于预防或逆转LGSOC患者中MEK抑制剂耐药的出现。

{"title":"Co-targeting the PI3K-Akt pathway improves response to MEK inhibition in low-grade serous ovarian cancer cell lines","authors":"Rebekah M. Peplinski, Jesse D. Riordan, Jacob L. Schillo, Elizabeth C. Hannan, Silvana Pedra Nobre, Yasmin A. Lyons, Keely K. Ulmer, Michael J. Goodheart, Adam J. Dupuy","doi":"10.1016/j.ygyno.2025.11.016","DOIUrl":"10.1016/j.ygyno.2025.11.016","url":null,"abstract":"<div><h3>Objective</h3><div>Low-grade serous ovarian cancer (LGSOC) frequently harbors genetic alterations that activate the MAPK pathway, providing an oncogenic target for therapeutic intervention. Recent clinical trials utilizing inhibitors of MEK (a key mediator of MAPK signaling), particularly trametinib or avutometinib/defactinib combination, have shown efficacy in patients with recurrent LGSOC. Unfortunately, however, nearly all patients eventually develop therapeutic resistance and progressive disease, which confers a dismal prognosis. Here, we aim to characterize biological responses of LGSOC to MEK inhibition at the molecular level.</div></div><div><h3>Methods</h3><div>We performed a kinome-focused CRISPR knockout screen in LGSOC cell lines to identify synthetic lethal interactions between trametinib treatment and loss of specific protein kinases. Candidates were evaluated using western blotting and cell viability assays.</div></div><div><h3>Results</h3><div>CRISPR kinome screens identified several protein kinases, particularly within the PI3K-Akt pathway, whose loss correlated with outgrowth of trametinib-resistant LGSOC cell populations, indicative of synthetic lethal interaction. Western blotting confirmed upregulation of Akt signaling upon MEK inhibition in a panel of LGSOC cell lines, and preventing this upregulation by co-inhibiting AKT with capivasertib produced synergistic antiproliferative effects in vitro.</div></div><div><h3>Conclusion</h3><div>LGSOC responds to MEK inhibition by upregulating PI3K-Akt signaling, thereby promoting cell survival and proliferation. Our research identified significant upregulation of the PI3K-Akt pathway in response to MEK inhibition. While targeted inhibition of AKT had minimal impact alone, combination with MEK inhibitors produced strong synergistic suppression of proliferation in LGSOC cells. This combination strategy could potentially be used to prevent or reverse the emergence of MEK inhibitor resistance in LGSOC patients.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"204 ","pages":"Pages 194-201"},"PeriodicalIF":4.1,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145690479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Survival assessment of sentinel lymph node biopsy alone without lymphadenectomy for early cervical cancer in real-world data 在真实世界数据中，单纯前哨淋巴结活检而非淋巴结切除术治疗早期宫颈癌的生存评估。

IF 4.1 2区医学 Q1 OBSTETRICS & GYNECOLOGY

Gynecologic oncology

Pub Date : 2025-12-04 DOI: 10.1016/j.ygyno.2025.11.024

Koji Matsuo , Matthew W. Lee , Emmeline L. Friedman , Hadi Erfani , Alice J. Lee , Jennifer A. Yao , Alexia J. Ouzounian , Mariya Kobayashi , Shinya Matsuzaki , Michiko Kodama , Hiroyuki Kanao , Lynda D. Roman

Objective

The PHENIX-I clinical trial in China demonstrated that sentinel lymph node (SLN) biopsy alone without additional lymphadenectomy for early cervical cancer had oncologic outcomes non-inferior to SLN biopsy and additional lymphadenectomy. This study examined overall survival associated with SLN biopsy alone without additional lymphadenectomy for early cervical cancer using real-world data in the United States.

Methods

This retrospective cohort study queried the Commission-on-Cancer's National Cancer Database. The study population included 465 patients aged 18–65 years-old with cervical cancer (preoperative stage IA1 with lympho-vascular space invasion, IA2, IB1, and IIA1 with tumor size of ≤3 cm) who underwent primary radical hysterectomy and SLN biopsy from 2012 to 2022. Exposure was additional lymphadenectomy at SLN biopsy (SLN biopsy alone n = 231, SLN biopsy and additional lymphadenectomy n = 234). Outcome measure was overall survival, assessed with Cox proportional hazard regression model adjusting for preoperative factor-derived propensity score and postoperative confounders (pathological lymph node metastasis, radiotherapy, and chemotherapy).

Results

The 5-year overall survival rates were 98.6% (95% confidence interval 94.3 to 99.7) for the SLN biopsy alone group and 96.8% (95% confidence interval 93.0 to 98.6) for the SLN biopsy and additional lymphadenectomy group (P = .69). Adjusted-hazard ratio for SLN biopsy alone compared to SLN biopsy and additional lymphadenectomy was 0.94 (95% confidence interval 0.24 to 3.67). Exploratory analysis showed similar results for squamous histology, preoperative stage IB1 with tumor size of ≤3 cm, and robotic-assisted surgery (all, P > .05).

Conclusion

The results of this real-world data in the United States suggested that SLN biopsy alone without additional lymphadenectomy for early cervical cancer meeting the PHENIX-I trial criteria may not have negative effects on short-term overall survival, warranting further validation.

目的：中国的PHENIX-I临床试验表明，早期宫颈癌前哨淋巴结（SLN）活检不加淋巴结切除术的肿瘤预后不低于SLN活检加淋巴结切除术。本研究使用美国的真实世界数据，对早期宫颈癌单独进行SLN活检而不附加淋巴结切除术的总生存率进行了研究。方法：这项回顾性队列研究查询了癌症委员会的国家癌症数据库。研究人群包括465例年龄在18-65岁的宫颈癌患者（术前IA1期伴淋巴血管间隙浸润，IA2期，IB1期和IIA1期，肿瘤大小≤3cm），这些患者在2012 - 2022年间接受了原发性根治性子宫切除术和SLN活检。暴露是在SLN活检中进行额外的淋巴结切除术（单独SLN活检n = 231， SLN活检和额外淋巴结切除术n = 234）。结局指标为总生存率，采用Cox比例风险回归模型对术前因素衍生倾向评分和术后混杂因素（病理性淋巴结转移、放疗和化疗）进行调整。结果：单纯SLN活检组的5年总生存率为98.6%(95%可信区间94.3 ~ 99.7)，SLN活检加淋巴结切除术组的5年总生存率为96.8%(95%可信区间93.0 ~ 98.6)（P = 0.69）。单纯SLN活检与SLN活检加淋巴结切除术的校正风险比为0.94（95%可信区间0.24 - 3.67）。探索性分析显示，在鳞状组织学、术前肿瘤大小≤3cm的IB1期和机器人辅助手术中，结果相似（均P < 0.05）。结论：美国真实世界数据的结果表明，满足PHENIX-I试验标准的早期宫颈癌，单纯SLN活检而不附加淋巴结切除术可能不会对短期总生存产生负面影响，需要进一步验证。

{"title":"Survival assessment of sentinel lymph node biopsy alone without lymphadenectomy for early cervical cancer in real-world data","authors":"Koji Matsuo , Matthew W. Lee , Emmeline L. Friedman , Hadi Erfani , Alice J. Lee , Jennifer A. Yao , Alexia J. Ouzounian , Mariya Kobayashi , Shinya Matsuzaki , Michiko Kodama , Hiroyuki Kanao , Lynda D. Roman","doi":"10.1016/j.ygyno.2025.11.024","DOIUrl":"10.1016/j.ygyno.2025.11.024","url":null,"abstract":"<div><h3>Objective</h3><div>The PHENIX-I clinical trial in China demonstrated that sentinel lymph node (SLN) biopsy alone without additional lymphadenectomy for early cervical cancer had oncologic outcomes non-inferior to SLN biopsy and additional lymphadenectomy. This study examined overall survival associated with SLN biopsy alone without additional lymphadenectomy for early cervical cancer using real-world data in the United States.</div></div><div><h3>Methods</h3><div>This retrospective cohort study queried the Commission-on-Cancer's National Cancer Database. The study population included 465 patients aged 18–65 years-old with cervical cancer (preoperative stage IA1 with lympho-vascular space invasion, IA2, IB1, and IIA1 with tumor size of ≤3 cm) who underwent primary radical hysterectomy and SLN biopsy from 2012 to 2022. Exposure was additional lymphadenectomy at SLN biopsy (SLN biopsy alone <em>n</em> = 231, SLN biopsy and additional lymphadenectomy <em>n</em> = 234). Outcome measure was overall survival, assessed with Cox proportional hazard regression model adjusting for preoperative factor-derived propensity score and postoperative confounders (pathological lymph node metastasis, radiotherapy, and chemotherapy).</div></div><div><h3>Results</h3><div>The 5-year overall survival rates were 98.6% (95% confidence interval 94.3 to 99.7) for the SLN biopsy alone group and 96.8% (95% confidence interval 93.0 to 98.6) for the SLN biopsy and additional lymphadenectomy group (<em>P</em> = .69). Adjusted-hazard ratio for SLN biopsy alone compared to SLN biopsy and additional lymphadenectomy was 0.94 (95% confidence interval 0.24 to 3.67). Exploratory analysis showed similar results for squamous histology, preoperative stage IB1 with tumor size of ≤3 cm, and robotic-assisted surgery (all, <em>P</em> > .05).</div></div><div><h3>Conclusion</h3><div>The results of this real-world data in the United States suggested that SLN biopsy alone without additional lymphadenectomy for early cervical cancer meeting the PHENIX-I trial criteria may not have negative effects on short-term overall survival, warranting further validation.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"204 ","pages":"Pages 174-183"},"PeriodicalIF":4.1,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145687229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of pembrolizumab with or without lenvatinib in recurrent uterine carcinosarcoma: a real-world single-center study 派姆单抗联合或不联合lenvatinib治疗复发性子宫癌肉瘤的疗效和安全性：一项真实世界的单中心研究

IF 4.1 2区医学 Q1 OBSTETRICS & GYNECOLOGY

Gynecologic oncology

Pub Date : 2025-12-04 DOI: 10.1016/j.ygyno.2025.11.017

Seongyun Lim, Young Eun Chung, Jun-Hyeong Seo, Yooyoung Lee, Tae-Joong Kim, Jeong-Won Lee, Byoung-Gie Kim , Chel-Hun Choi

Objective

Uterine carcinosarcoma (UCS) is a rare, aggressive endometrial cancer with limited treatment options for recurrence. The role of immunotherapy in UCS remains unclear. This study aimed to evaluate the efficacy and safety of pembrolizumab with or without lenvatinib in recurrent UCS.

Methods

We retrospectively analyzed 43 patients with recurrent UCS treated with pembrolizumab monotherapy (n = 9) or in combination with lenvatinib (n = 34) at a single center between 2018 and 2025. We analyzed clinicopathologic features, treatment response, survival outcomes and adverse events (AEs) graded per the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.

Results

Median progression-free survival (PFS) was 5 months and overall survival (OS) was 14 months. Objective response rate (ORR) was 37.5 % and disease control rate (DCR) was 67.5 %. The combination showed longer median PFS (5 vs. 3 months) and OS (19 vs. 7 months) compared with monotherapy, without statistical significance (PFS p = 0.99; OS p = 0.25). In exploratory multivariable analyses, larger tumor size was associated with shorter PFS (HR 2.73, 95 % CI 1.18–6.28) and OS (HR 5.36, 95 % CI 1.84–15.63). The most frequent AEs were hand-foot syndrome (29.4 %) and hypothyroidism (26.5 %), but no treatment-related deaths were observed.

Conclusions

Pembrolizumab with or without lenvatinib demonstrated modest efficacy with a manageable safety profile in recurrent UCS, although monotherapy outcomes remain exploratory due to the small sample size. This real-world study supports the potential role of immunotherapy for select UCS patients and highlights the need for prospective trials.

目的：子宫癌肉瘤（UCS）是一种罕见的侵袭性子宫内膜癌，复发治疗方案有限。免疫治疗在UCS中的作用尚不清楚。本研究旨在评估派姆单抗联合或不联合lenvatinib治疗复发性UCS的疗效和安全性。方法：我们回顾性分析了2018年至2025年在单中心接受派姆单抗单药治疗（n = 9）或联合lenvatinib （n = 34）的43例复发性UCS患者。我们根据不良事件通用术语标准（CTCAE） v5.0分析了临床病理特征、治疗反应、生存结局和不良事件（ae）。中位无进展生存期（PFS）为5个月，总生存期（OS）为14个月。客观有效率（ORR）为37.5%，疾病控制率（DCR）为67.5%。与单药治疗相比，联合治疗的中位PFS（5个月vs 3个月）和OS（19个月vs 7个月）更长，但无统计学意义（PFS p = 0.99; OS p = 0.25）。在探索性多变量分析中，较大的肿瘤大小与较短的PFS （HR 2.73, 95% CI 1.18-6.28）和OS （HR 5.36, 95% CI 1.84-15.63）相关。最常见的ae是手足综合征（29.4%）和甲状腺功能减退（26.5%），但未观察到与治疗相关的死亡。结论：Pembrolizumab联合lenvatinib或不联合lenvatinib在复发性UCS中表现出适度的疗效和可管理的安全性，尽管由于样本量小，单药治疗的结果仍处于探索性阶段。这项现实世界的研究支持免疫疗法对选择性UCS患者的潜在作用，并强调了前瞻性试验的必要性。

{"title":"Efficacy and safety of pembrolizumab with or without lenvatinib in recurrent uterine carcinosarcoma: a real-world single-center study","authors":"Seongyun Lim, Young Eun Chung, Jun-Hyeong Seo, Yooyoung Lee, Tae-Joong Kim, Jeong-Won Lee, Byoung-Gie Kim , Chel-Hun Choi","doi":"10.1016/j.ygyno.2025.11.017","DOIUrl":"10.1016/j.ygyno.2025.11.017","url":null,"abstract":"<div><h3>Objective</h3><div>Uterine carcinosarcoma (UCS) is a rare, aggressive endometrial cancer with limited treatment options for recurrence. The role of immunotherapy in UCS remains unclear. This study aimed to evaluate the efficacy and safety of pembrolizumab with or without lenvatinib in recurrent UCS.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed 43 patients with recurrent UCS treated with pembrolizumab monotherapy (<em>n</em> = 9) or in combination with lenvatinib (<em>n</em> = 34) at a single center between 2018 and 2025. We analyzed clinicopathologic features, treatment response, survival outcomes and adverse events (AEs) graded per the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.</div></div><div><h3>Results</h3><div>Median progression-free survival (PFS) was 5 months and overall survival (OS) was 14 months. Objective response rate (ORR) was 37.5 % and disease control rate (DCR) was 67.5 %. The combination showed longer median PFS (5 vs. 3 months) and OS (19 vs. 7 months) compared with monotherapy, without statistical significance (PFS <em>p</em> = 0.99; OS <em>p</em> = 0.25). In exploratory multivariable analyses, larger tumor size was associated with shorter PFS (HR 2.73, 95 % CI 1.18–6.28) and OS (HR 5.36, 95 % CI 1.84–15.63). The most frequent AEs were hand-foot syndrome (29.4 %) and hypothyroidism (26.5 %), but no treatment-related deaths were observed.</div></div><div><h3>Conclusions</h3><div>Pembrolizumab with or without lenvatinib demonstrated modest efficacy with a manageable safety profile in recurrent UCS, although monotherapy outcomes remain exploratory due to the small sample size. This real-world study supports the potential role of immunotherapy for select UCS patients and highlights the need for prospective trials.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"204 ","pages":"Pages 165-173"},"PeriodicalIF":4.1,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145687287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

First experience with intraperitoneal 224Ra-labeled microparticles after cytoreductive surgery in patients with peritoneal recurrence of platinum-sensitive epithelial ovarian cancer 铂敏感上皮性卵巢癌腹膜复发患者行细胞减缩手术后腹腔注射224ra标记微粒的首次经验

IF 4.1 2区医学 Q1 OBSTETRICS & GYNECOLOGY

Gynecologic oncology

Pub Date : 2025-12-04 DOI: 10.1016/j.ygyno.2025.11.018

Yun Wang , Els Van Nieuwenhuysen , Mona-Elisabeth Revheim , Christophe M. Deroose , Ane Gerda Zahl Eriksson , Brynhildur Eyjolfsdottir , Toon Van Gorp , Thaïs Baert , Anne-Kirsti Aksnes , Kari Myren , Ignace Vergote , Øyvind S. Bruland

Objective

The aim of this Phase 1 study was to evaluate safety and tolerability of the alpha emitting therapy ²²⁴Ra-labeled microparticles (Radspherin®) and to establish the recommended dose for further development.

Methods

The study was conducted in patients who had undergone complete resection of platinum-sensitive recurrent ovarian cancer. A single dose of Radspherin was administered intraperitoneally one to three days after surgery. Dose escalation (3 + 3 design) was performed at 1, 2, 4 and 7 MBq. Safety and tolerability of Radspherin after 12 months are presented.

Results

Fourteen patients were enrolled across the 4 dose levels. Median age was 66 (56–77) years. Median peritoneal cancer index at the start of the surgery was 7 (3–16). No dose limiting toxicity (DLT) was observed.

A total of 98 treatment emergent adverse events were reported (95 grade 1 or 2, and 3 grade 3). The three grade 3 events were cases of ileus (2) and anaemia (1) and were reported as unrelated to Radspherin by the investigators. One grade 2 serious adverse event of procedural complication (disconnect syringe-catheter) was reported as related to Radspherin. At 12-months, none of the patients had experienced peritoneal disease progression.

Conclusions

All dose levels were well tolerated, with no DLT observed. The highest activity dose of 7 MBq was selected as recommended dose for an expansion cohort. No grade ≥ 3 adverse events related to Radspherin were reported.

Clinical trial information

NCT03732768

目的：这项i期研究的目的是评估α释放疗法224ra标记微颗粒（Radspherin®）的安全性和耐受性，并确定进一步开发的推荐剂量。方法：研究对象为铂敏感的复发性卵巢癌完全切除患者。Radspherin在术后1 - 3天腹腔注射单剂量Radspherin。剂量递增（3 + 3设计）在1,2,4和7mbq进行。介绍了Radspherin在12个月后的安全性和耐受性。结果：14名患者被纳入4个剂量水平。中位年龄为66岁（56-77岁）。手术开始时腹膜癌中位指数为7（3-16）。未观察到剂量限制性毒性（DLT）。总共报告了98例治疗紧急不良事件（95例1级或2级，3例3级）。三个3级事件是肠梗阻（2例）和贫血（1例），研究人员报告与Radspherin无关。报告1例与Radspherin相关的2级严重手术并发症（注射器-导管断开）。12个月时，没有患者出现腹膜疾病进展。结论：所有剂量水平均耐受良好，未观察到DLT。7 MBq的最高活性剂量被选为扩展队列的推荐剂量。无与Radspherin相关的≥3级不良事件报道。临床试验信息：NCT03732768。

{"title":"First experience with intraperitoneal 224Ra-labeled microparticles after cytoreductive surgery in patients with peritoneal recurrence of platinum-sensitive epithelial ovarian cancer","authors":"Yun Wang , Els Van Nieuwenhuysen , Mona-Elisabeth Revheim , Christophe M. Deroose , Ane Gerda Zahl Eriksson , Brynhildur Eyjolfsdottir , Toon Van Gorp , Thaïs Baert , Anne-Kirsti Aksnes , Kari Myren , Ignace Vergote , Øyvind S. Bruland","doi":"10.1016/j.ygyno.2025.11.018","DOIUrl":"10.1016/j.ygyno.2025.11.018","url":null,"abstract":"<div><h3>Objective</h3><div>The aim of this Phase 1 study was to evaluate safety and tolerability of the alpha emitting therapy <sup>224</sup>Ra-labeled microparticles (Radspherin®) and to establish the recommended dose for further development.</div></div><div><h3>Methods</h3><div>The study was conducted in patients who had undergone complete resection of platinum-sensitive recurrent ovarian cancer. A single dose of Radspherin was administered intraperitoneally one to three days after surgery. Dose escalation (3 + 3 design) was performed at 1, 2, 4 and 7 MBq. Safety and tolerability of Radspherin after 12 months are presented.</div></div><div><h3>Results</h3><div>Fourteen patients were enrolled across the 4 dose levels. Median age was 66 (56–77) years. Median peritoneal cancer index at the start of the surgery was 7 (3–16). No dose limiting toxicity (DLT) was observed.</div><div>A total of 98 treatment emergent adverse events were reported (95 grade 1 or 2, and 3 grade 3). The three grade 3 events were cases of ileus (2) and anaemia (1) and were reported as unrelated to Radspherin by the investigators. One grade 2 serious adverse event of procedural complication (disconnect syringe-catheter) was reported as related to Radspherin. At 12-months, none of the patients had experienced peritoneal disease progression.</div></div><div><h3>Conclusions</h3><div>All dose levels were well tolerated, with no DLT observed. The highest activity dose of 7 MBq was selected as recommended dose for an expansion cohort. No grade ≥ 3 adverse events related to Radspherin were reported.</div></div><div><h3>Clinical trial information</h3><div><span><span>NCT03732768</span><svg><path></path></svg></span></div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"204 ","pages":"Pages 158-164"},"PeriodicalIF":4.1,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145687223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Frailty and body composition as predictors of postoperative outcomes in patients with epithelial ovarian cancer undergoing neoadjuvant chemotherapy 在接受新辅助化疗的上皮性卵巢癌患者中，虚弱和身体成分作为术后预后的预测因子。

IF 4.1 2区医学 Q1 OBSTETRICS & GYNECOLOGY

Gynecologic oncology

Pub Date : 2025-12-03 DOI: 10.1016/j.ygyno.2025.11.004

Jennifer Hansen , Jessica Suratkal , Shetal N. Shah MD , Johanna Kelley , Meng Yao , Nicole Wood , Molly Morton , Swapna Kollikonda , Hannah Barnard , Mariam AlHilli

Objective

To assess whether the five-factor modified frailty index (mFI5) can predict adverse post-operative outcomes in patients with epithelial ovarian cancer (EOC) undergoing interval cytoreductive surgery (CRS) and if CT-based body composition parameters are correlated with frailty.

Methods

A single-institution, retrospective cohort study of EOC patients undergoing interval CRS was performed. Demographic and clinical data were collected. Body composition was measured on pretreatment CT scans and reported as subcutaneous adipose tissue area (SAT), visceral adipose tissue area (VAT), and skeletal muscle index (SMI). Patients were classified using mFI5 into frail (mFI5 ≥ 2) vs. non-frail (mFI5 0–1) cohorts. Postoperative complications, non-home discharge, body composition parameters, progression-free survival (PFS) and overall survival (OS) were compared between cohorts.

Results

Among 179 patients evaluated, 33 patients (18.4 %) were classified as frail, and 146 (81.5 %) were non-frail. Frail patients had significantly higher rates of comorbidities and lower performance status (p < 0.001), but no difference in postoperative complications or non-home discharge was identified. Patients with frailty were more likely to have a higher VAT and SAT area on CT, while SMI was similar among the two cohorts. No statistically significant difference in PFS or OS was observed among frail and non-frail patients.

Conclusions

Frailty as assessed by mFI5 was identified in 18.4 % of patients undergoing interval CRS in our study and was not associated with non-home discharge, postoperative complications or survival. We identified a potential link between frailty and metabolic dysregulation, represented by higher VAT and SAT on CT scans.

目的：评价五因素修正虚弱指数（mFI5）能否预测间断性细胞减少手术（CRS）上皮性卵巢癌（EOC）患者术后不良结局，以及基于ct的体成分参数是否与虚弱相关。方法：对接受间歇CRS的EOC患者进行单机构、回顾性队列研究。收集了人口统计学和临床数据。通过预处理CT扫描测量身体成分，并报告皮下脂肪组织面积（SAT）、内脏脂肪组织面积（VAT）和骨骼肌指数（SMI）。使用mFI5将患者分为虚弱组（mFI5≥2）和非虚弱组（mFI5 0-1）。比较两组患者术后并发症、非居家出院、身体组成参数、无进展生存期（PFS）和总生存期（OS）。结果：179例患者中，体弱33例（18.4%），非体弱146例（81.5%）。结论：在我们的研究中，mFI5评估的衰弱患者在18.4%的间歇CRS患者中被发现，并且与非家庭出院、术后并发症或生存无关。我们确定了虚弱和代谢失调之间的潜在联系，在CT扫描上表现为更高的VAT和SAT。

{"title":"Frailty and body composition as predictors of postoperative outcomes in patients with epithelial ovarian cancer undergoing neoadjuvant chemotherapy","authors":"Jennifer Hansen , Jessica Suratkal , Shetal N. Shah MD , Johanna Kelley , Meng Yao , Nicole Wood , Molly Morton , Swapna Kollikonda , Hannah Barnard , Mariam AlHilli","doi":"10.1016/j.ygyno.2025.11.004","DOIUrl":"10.1016/j.ygyno.2025.11.004","url":null,"abstract":"<div><h3>Objective</h3><div>To assess whether the five-factor modified frailty index (mFI5) can predict adverse post-operative outcomes in patients with epithelial ovarian cancer (EOC) undergoing interval cytoreductive surgery (CRS) and if CT-based body composition parameters are correlated with frailty.</div></div><div><h3>Methods</h3><div>A single-institution, retrospective cohort study of EOC patients undergoing interval CRS was performed. Demographic and clinical data were collected. Body composition was measured on pretreatment CT scans and reported as subcutaneous adipose tissue area (SAT), visceral adipose tissue area (VAT), and skeletal muscle index (SMI). Patients were classified using mFI5 into frail (mFI5 ≥ 2) vs. non-frail (mFI5 0–1) cohorts. Postoperative complications, non-home discharge, body composition parameters, progression-free survival (PFS) and overall survival (OS) were compared between cohorts.</div></div><div><h3>Results</h3><div>Among 179 patients evaluated, 33 patients (18.4 %) were classified as frail, and 146 (81.5 %) were non-frail. Frail patients had significantly higher rates of comorbidities and lower performance status (<em>p</em> < 0.001), but no difference in postoperative complications or non-home discharge was identified. Patients with frailty were more likely to have a higher VAT and SAT area on CT, while SMI was similar among the two cohorts. No statistically significant difference in PFS or OS was observed among frail and non-frail patients.</div></div><div><h3>Conclusions</h3><div>Frailty as assessed by mFI5 was identified in 18.4 % of patients undergoing interval CRS in our study and was not associated with non-home discharge, postoperative complications or survival. We identified a potential link between frailty and metabolic dysregulation, represented by higher VAT and SAT on CT scans<strong>.</strong></div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"204 ","pages":"Pages 143-149"},"PeriodicalIF":4.1,"publicationDate":"2025-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145677419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Letter regarding “EUROArray HPV test accuracy for cervical precancer in self- vs. clinician-collected samples using the VALHUDES protocol” 关于“EUROArray HPV检测在使用VALHUDES方案的自我和临床采集样本中检测宫颈癌前病变的准确性”的信函。

IF 4.1 2区医学 Q1 OBSTETRICS & GYNECOLOGY

Gynecologic oncology

Pub Date : 2025-12-01 DOI: 10.1016/j.ygyno.2025.10.004

S. Dhanya Dedeepya , Vaishali Goel , Nivedita Nikhil Desai

引用次数: 0

Who is following up? Rethinking survivorship and surveillance 谁在跟进？重新思考幸存者和监视。

IF 4.1 2区医学 Q1 OBSTETRICS & GYNECOLOGY

Gynecologic oncology

Pub Date : 2025-12-01 DOI: 10.1016/j.ygyno.2025.11.019

L. Chen